Vinpocetine and eburn amonine derivatives for promoting bone growth

A method of treating renal damage, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula I:

• wherein
• each of R1, R2, R5, R7 and R8 are independently selected from the group consisting of H, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkoxy, C1-6 alkyl-hydroxy, —OR1a, —C(O)R1a, —C(O)OR1a, —C(O)NR1aR1b, —NR1aR1b, —SR1a, —N(R1a)C(O)R1b, —N(R1a)C(O)OR1b, —N(R1a)C(O)NR1aR1b, —OP(O)(OR1a)2, —S(O)2OR1a, —S(O)2NR1aR1b, —CN, —CH═N—OH, C1-6 alkyl-OC(O)-aryl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl;
• alternatively, R1 is combined with R2 to form ═O or ═NR1a, R1 is combined with R3 to form a bond, or R1 is combined with R5 to form a cycloalkyl;
• each R1a and R1b is independently selected from the group consisting of H, C1-6 alkyl, C1-6 alkyl-hydroxy, C1-6 alkyl-NO2, C1-6 alkyl-cycloalkyl, heterocycloalkyl, and heteroaryl;
• each of R3 and R4 are independently selected from the group consisting of H, C1-6 alkyl and C1-6 haloalkyl;
• alternatively two R5 or R7 groups attached to the same carbon can be combined to form ═O;
• R6 is absent or an N-oxide;
• and
• salts, hydrates and isomers thereof, thereby treating renal damage in the subject.

A method of treating cancer, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula I:

• wherein
• each of R1, R2, R5, R7 and R8 are independently selected from the group consisting of H, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkoxy, C1-6 alkyl-hydroxy, —C(O)R1a, —C(O)OR1a, —C(O)NR1aR1b, —NR1aR1b, —SR1a, —N(R1a)C(O)R1b, —N(R1a)C(O)OR1b, —N(R1a)C(O)NR1aR1b, —OP(O)(OR1a)2, —S(O)2OR1a, —S(O)2NR1aR1b, —CN, —CH═N—OH, C1-6 alkyl-OC(O)-aryl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl;
• alternatively, R1 is combined with R2 to form ═O or ═NR1a, R1 is combined with R3 to form a bond, or R1 is combined with R5 to form a cycloalkyl;
• each R1a and R1b is independently selected from the group consisting of H, C1-6 alkyl, C1-6 alkyl-hydroxy, C1-6 alkyl-NO2, C1-6 alkyl-cycloalkyl, heterocycloalkyl, and heteroaryl;
• each of R3 and R4 are independently selected from the group consisting of H, C1-6 alkyl and C1-6 haloalkyl;
• alternatively two R5 or R7 groups attached to the same carbon can be combined to form ═O;
• R6 is absent or an N-oxide;
• and
• salts, hydrates and isomers thereof, thereby promoting bone growth in the subject.